10x Genomics [TXG] vs Schrodinger [SDGR] Detailed Stock Comparison
10x Genomics
NASDAQ
Loading...
Schrodinger
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: 10x Genomics wins in 15 metrics, Schrodinger wins in 3 metrics, with 0 ties. 10x Genomics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | 10x Genomics | Schrodinger | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -9.41 | 44.39 | 10x Genomics |
| Price-to-Book Ratio | 2.30 | 4.36 | 10x Genomics |
| Debt-to-Equity Ratio | 11.22 | 33.38 | 10x Genomics |
| PEG Ratio | 0.05 | -2.19 | Schrodinger |
| EV/EBITDA | -11.46 | -5.93 | 10x Genomics |
| Profit Margin (TTM) | -13.13% | -76.22% | 10x Genomics |
| Operating Margin (TTM) | -2.63% | -96.61% | 10x Genomics |
| Return on Equity | -11.30% | -44.40% | 10x Genomics |
| Return on Assets (TTM) | -9.45% | -17.52% | 10x Genomics |
| Free Cash Flow (TTM) | $-6.73M | $-164.68M | 10x Genomics |
| 1-Year Return | -39.12% | 2.26% | Schrodinger |
| Price-to-Sales Ratio (TTM) | 2.76 | 6.29 | 10x Genomics |
| Enterprise Value | $1.27B | $1.11B | 10x Genomics |
| EV/Revenue Ratio | 1.97 | 4.65 | 10x Genomics |
| Gross Profit Margin (TTM) | 72.34% | 47.77% | 10x Genomics |
| Revenue per Share (TTM) | $5 | $3 | 10x Genomics |
| Earnings per Share (Diluted) | $-0.70 | $-2.48 | 10x Genomics |
| Beta (Stock Volatility) | 2.03 | 1.68 | Schrodinger |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
10x Genomics vs Schrodinger Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| 10x Genomics | 9.16% | 7.04% | 10.08% | 67.45% | 26.66% | 0.78% |
| Schrodinger | 3.75% | 4.85% | -10.76% | -4.24% | -6.32% | -0.39% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| 10x Genomics | -39.12% | -59.01% | -87.04% | -72.64% | -72.64% | -72.64% |
| Schrodinger | 2.26% | -26.62% | -67.06% | -36.34% | -36.34% | -36.34% |
Performance & Financial Health Analysis: 10x Genomics vs Schrodinger
| Metric | TXG | SDGR |
|---|---|---|
| Market Information | ||
| Market Cap | $1.78B | $1.50B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 3,557,051 | 1,671,542 |
| 90 Day Avg. Volume | 3,267,257 | 1,316,884 |
| Last Close | $14.30 | $20.32 |
| 52 Week Range | $6.78 - $24.76 | $16.60 - $28.47 |
| % from 52W High | -42.25% | -28.64% |
| All-Time High | $208.99 (Jun 28, 2021) | $117.00 (Feb 22, 2021) |
| % from All-Time High | -93.16% | -82.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.13% | 0.16% |
| Quarterly Earnings Growth | 0.13% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | -0.13% | -0.76% |
| Operating Margin (TTM) | -0.03% | -0.97% |
| Return on Equity (TTM) | -0.11% | -0.44% |
| Debt to Equity (MRQ) | 11.22 | 33.38 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.21 | $4.66 |
| Cash per Share (MRQ) | $3.59 | $6.12 |
| Operating Cash Flow (TTM) | $66.95M | $27.50M |
| Levered Free Cash Flow (TTM) | $58.22M | $-6,255,750 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: 10x Genomics vs Schrodinger
| Metric | TXG | SDGR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -9.41 | 44.39 |
| Forward P/E | -11.72 | -8.22 |
| PEG Ratio | 0.05 | -2.19 |
| Price to Sales (TTM) | 2.76 | 6.29 |
| Price to Book (MRQ) | 2.30 | 4.36 |
| Market Capitalization | ||
| Market Capitalization | $1.78B | $1.50B |
| Enterprise Value | $1.27B | $1.11B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.97 | 4.65 |
| Enterprise to EBITDA | -11.46 | -5.93 |
| Risk & Other Metrics | ||
| Beta | 2.03 | 1.68 |
| Book Value per Share (MRQ) | $6.21 | $4.66 |
Financial Statements Comparison: 10x Genomics vs Schrodinger
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TXG | SDGR |
|---|---|---|
| Revenue/Sales | $154.88M | $59.55M |
| Cost of Goods Sold | $49.44M | $28.43M |
| Gross Profit | $105.45M | $31.12M |
| Research & Development | $64.25M | $45.84M |
| Operating Income (EBIT) | $-48.53M | $-50.89M |
| EBITDA | $-32.89M | $-36.21M |
| Pre-Tax Income | $-33.51M | $-59.78M |
| Income Tax | $852,000 | $28,000 |
| Net Income (Profit) | $-34.36M | $-59.81M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TXG | SDGR |
|---|---|---|
| Cash & Equivalents | $377.06M | $326.00M |
| Total Current Assets | $579.73M | $570.94M |
| Total Current Liabilities | $107.90M | $165.47M |
| Long-Term Debt | $70.63M | $99.41M |
| Total Shareholders Equity | $706.90M | $373.50M |
| Retained Earnings | $-1.50B | $-585.35M |
| Property, Plant & Equipment | $55.58M | $132.60M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TXG | SDGR |
|---|---|---|
| Operating Cash Flow | $35.44M | $153.46M |
| Capital Expenditures | $-1.89M | $-596,000 |
| Free Cash Flow | $32.46M | $143.47M |
| Debt Repayment | N/A | $-14,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TXG | SDGR |
|---|---|---|
| Shares Short | 14.46M | 9.34M |
| Short Ratio | 4.59 | 9.36 |
| Short % of Float | 0.19% | 0.23% |
| Average Daily Volume (10 Day) | 3,557,051 | 1,671,542 |
| Average Daily Volume (90 Day) | 3,267,257 | 1,316,884 |
| Shares Outstanding | 122.29M | 72.87M |
| Float Shares | 112.38M | 57.82M |
| % Held by Insiders | 0.02% | 0.03% |
| % Held by Institutions | 1.05% | 1.08% |
Dividend Analysis & Yield Comparison: 10x Genomics vs Schrodinger
| Metric | TXG | SDGR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |